Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
Permanent URI for this communityhttps://hdl.handle.net/11727/4806
Browse
2 results
Search Results
Item Economic Burden of Severe Asthma in Turkey: A Cost of Illness Study from Payer Perspective(2021) Bavbek, S.; Malhan, S.; Mungan, D.; Misirligil, Z.; Erdinc, M.; Gemicioglu, B.; Oguzulgen, I. Kivilcim; Oksuz, E.; Yildiz, F.; Yorgancioglu, A.; 0000-0002-5723-5965; 32372589; K-8238-2012Objective. To estimate economic burden of severe asthma in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods. This cost of illness study was based on identification of per patient annual direct medical costs for the management of severe asthma in Take, from payer perspective. Average per patient direct medical cost was calculated based on cost items related to outpatient visits laboratory and radiological tests, hospitalizations and interventions drug treatment and equipment, and co-morbidities/complications. Results. Based on total annual per patient costs calculated for outpatient admission ($177.91), laboratory and radiological tests ($ 8232), hospitalization/interventions ($1,154.55), drug treatment/equipment ($2,289.63) and co-morbidities ($ 661.39) cost items, total per patient annual direct medical cost related to management of severe asthma was calculated to be $ 4,369.76 from payer perspective. Drug treatment/equipment (524%) was the main cost driver in the management of severe asthma in Turkey, as followed by hospitalizations/interventions (264%) and co-morbidities (15.2%). Conclusions. In conclusion, our findings indicate that managing patients with severe asthma pose a considerable burden to health economics in Turkey with medications as the main cost driver.Item Evaluation of choroidal thickness in children with acute asthma attack by optical coherence tomography(2021) Kurultay, Isil; Sancakli, Ozlem; 34482738Objective: To evaluate the change in central choroidal thickness in children with asthma attack before and after treatment with beta(2) agonists. Materials and methods: About 100 eyes of 50 patients (5-17 years old) with visual acuity of 20/20 who had no retinal, choroidal, and systemic comorbidity were examined by enhanced depth optical coherence tomography (EDI-OCT) before and after asthma attack treatment. Sixty eyes of 30 healthy children of similar age and gender were evaluated as the control group. The central choroidal thickness, peak expiratory flow (PEF), forced expiratory volume 1(FEV1), oxygen saturation, and heart rate were evaluated. Results: The mean age of the patients was 9.2 +/- 3.1 years, and the mean saturation values of patients was 97.2 +/- 1.3 before treatment, and it increased to 98.3 +/- 0.9 after treatment with a statistically significant difference. The mean FEV1 values were 80.8 +/- 15.2 before, and 92.7 +/- 12.9 after the treatment and PEF values were 75.9 +/- 18.6 before and 89.3 +/- 18.9 after treatment. This differences were statistically significant (p < 0.001). The average choroidal thickness before the treatment were 310.4 +/- 34.2 mu m and decreased to 302.7 +/- 34.4 mu m after the treatment, this decrease was statistically significant (p < 0.001). The mean choroidal thickness of the control group was 303.0 +/- 7.3 mu m and compared to the pre-treatment and post-treatment values, it was more similar to the post-treatment values, although there was no statistically difference. Conclusion: In our study, it was shown that choroidal thickness was significantly reduced in children with asthma who received attack treatment with beta(2) agonists, and it was similar to the control group after the treatment.